AAAAAA

   
Results: 1-15 |
Results: 15
Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide
Authors: Safgren, SL Reid, JM Rios, R Ames, MM
Citation: Sl. Safgren et al., Validated high-performance liquid chromatographic assay for simultaneous determination of dacarbazine and the plasma metabolites 5-(3-hydroxymethyl-3-methyl-1-triazeno)imidazole-4-carboxamide and 5-(3-methyl-1-triazeno)imidazole-4-carboxamide, J CHROMAT B, 754(1), 2001, pp. 91-96
A phase I clinical, pharmacological, and biological trial of interleukin 6plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: Enhanced hematological responses but a high incidence of grade III/IV constitutionaltoxicities
Authors: Bracho, F Krailo, MD Shen, V Bergeron, S Davenport, V Liu-Mares, W Blazar, BR Panoskaltsis-Mortari, A van de Ven, C Secola, R Ames, MM Reid, JM Reaman, GH Cairo, MS
Citation: F. Bracho et al., A phase I clinical, pharmacological, and biological trial of interleukin 6plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: Enhanced hematological responses but a high incidence of grade III/IV constitutionaltoxicities, CLIN CANC R, 7(1), 2001, pp. 58-67
Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2 '-deoxyuridine (IdUrd)
Authors: Galanis, E Goldberg, R Reid, J Atherton, P Sloan, J Pitot, H Rubin, J Adjei, AA Burch, P Safgren, SL Witzig, TE Ames, MM Erlichman, C
Citation: E. Galanis et al., Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2 '-deoxyuridine (IdUrd), ANN ONCOL, 12(5), 2001, pp. 701-707
The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectivelycytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells
Authors: Gilbert, JA Frederick, LM Ames, MM
Citation: Ja. Gilbert et al., The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectivelycytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells, CLIN CANC R, 6(11), 2000, pp. 4365-4372
The death of authentic primitive art and other tales of progress.
Authors: Ames, MM
Citation: Mm. Ames, The death of authentic primitive art and other tales of progress., CAN J SOC, 25(2), 2000, pp. 253-254
A randomized phase II and pharmacokinetic study of dacarbazine in patientswith recurrent glioma
Authors: Rajkumar, SV Reid, JM Novotny, PJ Safgren, SL Scheithauer, BW Johnson, PS Nair, S Morton, RF Hatfield, AK Krook, JE Ames, MM Buckner, JC
Citation: Sv. Rajkumar et al., A randomized phase II and pharmacokinetic study of dacarbazine in patientswith recurrent glioma, J NEURO-ONC, 49(3), 2000, pp. 255-261
Effect of 6-aminonicotinamide and other protein synthesis inhibitors on formation of platinum-DNA adducts and cisplatin sensitivity
Authors: Budihardjo, II Boerner, SA Eckdahl, S Svingen, PA Rios, R Ames, MM Kaufmann, SH
Citation: Ii. Budihardjo et al., Effect of 6-aminonicotinamide and other protein synthesis inhibitors on formation of platinum-DNA adducts and cisplatin sensitivity, MOLEC PHARM, 57(3), 2000, pp. 529-538
Metabolic activation of dacarbazine by human cytochromes P450: The role ofCYP1A1, CYP1A2, and CYP2E1
Authors: Reid, JM Kuffel, MJ Miller, JK Rios, R Ames, MM
Citation: Jm. Reid et al., Metabolic activation of dacarbazine by human cytochromes P450: The role ofCYP1A1, CYP1A2, and CYP2E1, CLIN CANC R, 5(8), 1999, pp. 2192-2197
Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors
Authors: Pitot, HC McElroy, EA Reid, JR Windebank, AJ Sloan, JA Erlichman, C Bagniewski, PG Walker, DL Rubin, J Goldberg, RM Adjei, AA Ames, MM
Citation: Hc. Pitot et al., Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors, CLIN CANC R, 5(3), 1999, pp. 525-531
Phase I study of topotecan administered as a 21-day continuous infusion inchildren with recurrent solid tumors: A report from the Children's Cancer Group
Authors: Frangoul, H Ames, MM Mosher, RB Reid, JM Krailo, MD Seibel, NL Shaw, DWW Steinherz, PG Whitlock, JA Holcenberg, JS
Citation: H. Frangoul et al., Phase I study of topotecan administered as a 21-day continuous infusion inchildren with recurrent solid tumors: A report from the Children's Cancer Group, CLIN CANC R, 5(12), 1999, pp. 3956-3962
Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model
Authors: Berg, SL Reid, J Godwin, K Murry, DJ Poplack, DG Balis, FM Ames, MM
Citation: Sl. Berg et al., Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model, J PED H ONC, 21(1), 1999, pp. 26-30
Indolocarbazole poisons of human topoisomerase I: Regioisomeric analogues of ED-110
Authors: Zembower, DE Zhang, HP Lineswala, JP Kuffel, MJ Aytes, SA Ames, MM
Citation: De. Zembower et al., Indolocarbazole poisons of human topoisomerase I: Regioisomeric analogues of ED-110, BIOORG MED, 9(2), 1999, pp. 145-150
Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma
Authors: Buckner, JC Malkin, MG Reed, E Cascino, TL Reid, JM Ames, MM Tong, WPY Lim, S Figg, WD
Citation: Jc. Buckner et al., Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma, MAYO CLIN P, 74(2), 1999, pp. 137-145
Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent
Authors: Walker, DL Reid, JM Svingen, PA Rios, R Covey, JM Alley, MC Hollingshead, MG Budihardjo, II Eckdahl, S Boerner, SA Kaufmann, SH Ames, MM
Citation: Dl. Walker et al., Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent, BIOCH PHARM, 58(6), 1999, pp. 1057-1066
Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma
Authors: Rajkumar, SV Buckner, JC Schomberg, PJ Reid, JM Bagniewski, PJ Ames, MM Cascino, TL Marks, RS
Citation: Sv. Rajkumar et al., Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma, INT J RAD O, 42(5), 1998, pp. 969-975
Risultati: 1-15 |